Clinical Trial: Phase 2 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07116746) titled 'Phase 2 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment' on Aug. 07.

Brief Summary: This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.

Study Start Date: Sept., 2025

Study Type: INTERVENT...